RE:RE:Phase 2/3 OV company Genelux trades at US$35.00Results from ONCY's Bracelet-1 Phase 2 study in heavily pre-treated metastatic breast cancer patients treated with the single agent pelareorep + chemotherapy showed:
- Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy
- 37.5% confirmed overall response rate with pelareorep-paclitaxel vs. 13.3% with paclitaxel monotherapy
-12-month progression-free survival rate of 32.8% for pelareorep-paclitaxel compared to 0% for paclitaxel monotherapy and 0% for pelareorep-paclitaxel-avelumab